Skip to main content
SpringerLink
Log in

Aktueller Stellenwert der zytoreduktiven Tumornephrektomie bei Patienten mit synchron metastasiertem Nierenzellkarzinom

Erkenntnisgewinn in kleinen Schritten

Current importance of cytoreductive tumor nephrectomy in patients with synchronous metastasized renal cell carcinoma

Knowledge gain in small steps

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076

    Article  PubMed  Google Scholar 

  2. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799

    Article  CAS  PubMed  Google Scholar 

  3. Ljungberg B, Albiges LK, Bensalah K et al (2017) Guidelines on renal cell carcinoma. European Association of Urology. http://uroweb.org/guideline/renal-cell-carcinoma/. Zugegriffen: 04.08.2017

    Google Scholar 

  4. Motzer RJ, Jonasch E, Agarwal N et al (2016) NCCN clinical practice guidelines in oncology (NCCN guidelines) kidney cancer, version 2. https://www.tri-kobe.org/nccn/guideline/urological/english/kidney.pdf. Zugegriffen: 04.08.2017

    Google Scholar 

  5. Ko JJ, Xie W, Kroeger N et al (2015) The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16(3):293–300

    Article  PubMed  Google Scholar 

  6. Faba OR, Brookman-May SD, Linares E et al (2017) Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. World J Urol. https://doi.org/10.1007/s00345-017-2072-y

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik, St. Elisabeth-Klinikum (SEK), St. Elisabeth-Str. 23, 94315, Straubing, Deutschland

    Matthias May

  2. Urologische Klinik, Carl-Thiem-Klinikum (CTK), Cottbus, Deutschland

    Ingmar Wolff

  3. Klinik für Urologie und Neurourologie, Unfallkrankenhaus Berlin (UKB), Berlin, Deutschland

    Ingmar Wolff

Authors
  1. Matthias May
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingmar Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias May.

Ethics declarations

Interessenkonflikt

M. May und I. Wolff geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

May, M., Wolff, I. Aktueller Stellenwert der zytoreduktiven Tumornephrektomie bei Patienten mit synchron metastasiertem Nierenzellkarzinom. Onkologe 23, 938–939 (2017). https://doi.org/10.1007/s00761-017-0285-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-017-0285-8

Search

Navigation